San Mateo, California–based Route 92 develops a suite of reperfusion and access systems leveraging the patented Tenzing delivery catheter. The products aim to improve the efficiency of endovascular thrombectomy procedures. The company designed its technology to enable the quick restoration of blood flow to the brain following acute ischemic stroke.
Tenzing delivery catheters — first clinically used in 2019 — have the protection of a global patent portfolio that includes 26 U.S. patents.
In October 2024, Route 92 filed suit against Q’Apel alleging the infringement of five U.S. patents. The suit, filed in the U.S. District Court for the District of Delaware, aimed to protect the Tenzing delivery catheters by alleging infringements with the Q’Apel Hippo aspiration system and Cheetah delivery tool.
Following the case’s settlement, Q’Apel permanently removed the Hippo-Cheetah product from the market.
“We are pleased with the resolution of this litigation,” said Dr. Tony Chou, founder and CEO of Route 92 Medical. “With more than 140 patents protecting our innovations worldwide, and numerous studies showing the best-in-class performance of our Tenzing-powered neurovascular intervention solutions, we remain committed to vigorously defending our intellectual property position should companies seek to replicate our products.”
